ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
67.527,37
-0,29%
Brent Oil
81,295
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Candel Therapeutics Inc (CADL)

  7. Candel Therapeutics Inc (CADL) Notícias

CADL

Candel Therapeutics (CADL)

Candel Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CADL
DataHoraFonteTítuloCódigoCompanhia
30/05/202418:20Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CADLCandel Therapeutics Inc
30/05/202417:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CADLCandel Therapeutics Inc
30/05/202417:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
30/05/202409:00GlobeNewswire Inc.FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
24/05/202408:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
23/05/202418:00GlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
22/05/202409:00GlobeNewswire Inc.Candel Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CADLCandel Therapeutics Inc
20/05/202409:00GlobeNewswire Inc.Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
14/05/202409:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CADLCandel Therapeutics Inc
14/05/202409:00GlobeNewswire Inc.Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
25/04/202409:00GlobeNewswire Inc.Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
11/04/202410:00GlobeNewswire Inc.Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
09/04/202409:00GlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsNASDAQ:CADLCandel Therapeutics Inc
04/04/202409:00GlobeNewswire Inc.Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
28/03/202417:05GlobeNewswire Inc.Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
28/03/202409:05GlobeNewswire Inc.Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
05/03/202418:30GlobeNewswire Inc.Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateNASDAQ:CADLCandel Therapeutics Inc
13/02/202409:30GlobeNewswire Inc.CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
05/02/202410:00GlobeNewswire Inc.Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and CatalystsNASDAQ:CADLCandel Therapeutics Inc
19/01/202410:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
12/12/202310:58Dow Jones NewsCandel Therapeutics Shares Soar After FDA Fast Track of CAN-2409NASDAQ:CADLCandel Therapeutics Inc
12/12/202310:00GlobeNewswire Inc.Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
30/11/202319:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
28/11/202311:00GlobeNewswire Inc.Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409NASDAQ:CADLCandel Therapeutics Inc
09/11/202310:00GlobeNewswire Inc.Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
04/11/202309:00GlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITCNASDAQ:CADLCandel Therapeutics Inc
03/11/202313:00GlobeNewswire Inc.Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
18/10/202312:00GlobeNewswire Inc.Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110NASDAQ:CADLCandel Therapeutics Inc
27/09/202310:40GlobeNewswire Inc.Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
26/09/202309:00GlobeNewswire Inc.Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung CancerNASDAQ:CADLCandel Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CADL

Seu Histórico Recente

LBNK
ELMOUSDT
Elmo
BIT
UC3F80
Unicredit Bank
GATE
PSTUSDT
Primas
AMEX
BSCT
Invesco Bulletshares 202...
NEO
FCGB.U
Fidelity Global Core Plu...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados